Table 4. Univariate and multivariate Cox regression for DFS of patients with HER2 tumours (n = 155).

	Univariate		Multivariate
Factor	HR (95% CI)	p	HR (95% CI)	p
Trastuzumab exposition
No	1
Yes	0.451 (0.228–0.891)	0.022
Trastuzumab exposition
≤292 days/no	1
>292 days	0.372 (0.178–0.778)	0.009
Trastuzumab exposition
<6 months/no	1
≥6 months	0.396 (0.193–0.811)	0.011
Trastuzumab exposition
<12 weeks/no	1
≥12 weeks	0.398 (0.197–0.804)	0.010
Trastuzumab exposition
≤9 weeks/no	1		1
>9 weeks	0.375 (0.186–0.757)	0.006	0.353 (0.175–0.714)	0.004
St. Gallen Consensus treatment
Inadequate	1
Adequate	0.448 (0.210–0.959)	0.039
pN
N−	1		1
N+	2.018 (1.042–3.908)	0.037	2.183 (1.124–4.237)	0.021